Clinical Trials

As Stoke prepares for a key investor conference, its lead drug zorevunersen nears a pivotal Phase 3 readout, promising a new era for patients and the RNA platform.

With Hepatitis C royalties declining, Enanta Pharmaceuticals faces investors this month to sell its vision: a future built on novel RSV and immunology drugs.

As it launches a pivotal trial for its MYC inhibitor, Persevere Therapeutics adds a seasoned CEO to its board, signaling a sharp focus on funding and strategy.

Monash Health's landmark deal with Germany's Data4Life isn't just about tech; it's a strategic play to redefine global clinical research using open-source power.

With its new COVID vaccine approved, Novavax is leveraging global partners like Sanofi to earn royalties, proving an asset-light model can rival industry giants.

GRI Bio showcases its promising IPF drug, GRI-0621, in a new webcast, aiming to capture investor and scientific attention before a key industry congress.

Cardurion is set to reveal pivotal Phase 2 data for Tovinontrine, a first-in-class drug aiming to help millions suffering from chronic heart failure.

Allegheny Health Network and START's new partnership isn't just a local win; it's a blueprint for a more accessible, patient-centric future in oncology.

A small biophysics firm unveils promising data for its at-home headset using magnetic fields to treat Long COVID, heralding a potential shift from pharma to biophysics.

As AN2 Therapeutics bets its future on novel boron-based drugs, the appointment of Dr. Cameron Trenor signals a critical shift from promise to proof.

PTC Therapeutics' Sephience isn't just another drug; it's a potential life-changer for PKU patients, promising to ease the burden of a lifelong restrictive diet.

A $1M award for a novel drug targeting mitochondrial dysfunction is more than just funding; it's a bet on a new paradigm for fighting neurodegeneration.

With federal funds backing its Phase 3 trial for a first-in-class cannabis withdrawal drug, PleoPharma offers a new model for biotech investment.

A 645% surge in contracts is just the headline. The real story is how NetraMark's 'explainable' AI is building trust and changing how we develop new cures.

With positive Phase 1 results, AC Immune's NLRP3 inhibitor not only targets neuro-inflammation but also bolsters the company's independent strategy.

Low patient enrollment cripples cancer research. Mednet’s new AI tool, TrialMatch, aims to fix this by seamlessly connecting oncologists to vital trials.

A novel therapy that disarms rather than kills a deadly superbug offers a glimpse of a post-antibiotic future for patients with a debilitating lung disease.

An acquisition signals more than growth; it’s a strategic redesign of the clinical trial landscape, challenging giants and empowering innovation.

By appointing Merck and Pfizer heavyweight Dr. David Strutton, Crescendo Health signals a major bid to monetize patient-centric data in the booming RWE market.

A landmark study validates Kandu's at-home IpsiHand, showing over half of chronic stroke patients can regain meaningful hand function years after injury.